Design, Synthesis, and Biological Evaluation of Benzimidazol‐2‐One Hybrids as Potential Anti‐Alzheimer's Disease Agents
Fatih Yılmaz, Emre Menteşe, Ozan Emre Eyüpoğlu, Bahittin Kahveci, Mustafa Emirik · 2026
Read Design, Synthesis, and Biological Evaluation of Benzimidazol‐2‐One Hybrids as Potential Anti‐Alzheimer's Disease Agents by Fatih Yılmaz, Emre Menteşe, Ozan Emre Eyüpoğlu, Bahittin Kahveci, Mustafa Emirik (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13492513.txt.
Description
Fatih Yilmaz and co-authors made a new set of drug-like compounds in 2026 as leads against Alzheimer's disease. The illness has many causes, so drugs that hit one target often help too little. Their compounds join three building blocks to a shared core and aim at three enzymes at once.
Tests showed some compounds slowed each enzyme at low doses, though less than known drugs. One lead was best for the first enzyme, and others led on the other two. Some also mopped up harmful free forms of oxygen. Early checks suggest a few could reach the brain. More work is needed before any could be a drug.
Catalog record
| CREATOR | Fatih Yılmaz, Emre Menteşe, Ozan Emre Eyüpoğlu, Bahittin Kahveci, Mustafa Emirik |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |